A personalized mRNA vaccine combined with Merck’s Keytruda cut the risk of melanoma recurrence or death by 42% over two years in a late-stage clinical trial. The findings, presented at the European Society for Medical Oncology meeting in Madrid, position the experimental therapy for potential regulatory approval next year.
When pharmaceutical giants Merck and Moderna released promising data on cancer vaccine trial results, financial markets and the oncology community reacted with two very different gears. On one side stood robust clinical figures: 82.2% of patients who received the custom-brewed vaccine alongside standard immunotherapy remained cancer-free at the two-year mark, compared with 70% among those receiving the immunotherapy alone, according to data from the INTerpath-001 trial.
On the other side stood nervous investors. Moderna shares dropped as much as 25% on a Thursday following an early data leak, capping off what analysts termed its worst week in three months. Merck stock slipped 0.8% to $149, dragged down not by poor medical efficacy, but by the weight of expectations built up after an initial topline announcement back in August.
Moderna and Merck’s personalized mRNA cancer vaccine reduced melanoma recurrence by 42%. We already have a vaccine that prevents cancer (HPV). Now we’re going to have vaccines individually targeted to treat your cancer. This is the same technology that our government cut NIH…
How INTerpath-001 Tested Intismeran Autogene in 1,137 Patients
The trial enrolled 1,137 patients with high-risk resected cutaneous melanoma across stages IIB to IV. Following surgery to remove their tumors, participants were randomized to receive either Merck’s immunotherapy drug pembrolizumab alone or paired with the experimental mRNA vaccine, known as intismeran autogene.
Each personalized vaccine is manufactured using genetic material from an individual patient’s tumor. The process identifies up to 34 distinct neoantigens—unique mutated proteins produced by the cancer cells—and encodes them into synthetic mRNA. Once injected, the vaccine instructs the body’s immune system to train T-cells specifically against those tumor markers, while pembrolizumab helps the immune system find and destroy cancer.
How to improve outcomes in patients with metastatic melanoma post-surgical resection, and specifically, vs controls:—Reduce 2-year mortality from 82 to 70%—Reduce recurrence by 42%Treat with a personalized mRNA neoantigen vaccine@statnews @adamfeuerstein…
Personalisation is the next step up and it’s really exciting, it’s a fabulous technology.
Prof Pippa Corrie, via BBC
Corrie noted that while the trial serves as a vital proof of principle, researchers must continue gathering data to verify broader applications.
Drugmakers Seek Regulatory Approval Despite Manufacturing Bottlenecks
Despite market volatility and an early data leak that triggered heavy trading activity—including rolling 24-hour volume topping $104 million on crypto platforms like Hyperliquid’s MRNA perpetual contract according to Tokenpost—both drugmakers are pushing forward. Executives confirmed they are engaging with regulatory authorities, opening a pathway to file for approvals in the US, Europe, and the UK as soon as next year.
Yet manufacturing scale remains a distinct bottleneck. Because every single dose is custom-brewed from a patient’s own genetic profile, the production cycle can take six weeks. Analysts have also raised flags over pricing. While exact commercial costs remain unconfirmed by the manufacturers—with Moderna and Merck declining to respond to a request about its cost—earlier financial reports suggested individual treatments could run around $200,000 per patient, a factor that will heavily influence adoption rates within universal healthcare systems like the UK NHS.
The Post-2028 Strategic Horizon for Merck
For Merck, the success of the intismeran combination carries heavy commercial weight beyond skin cancer. The pharmaceutical company’s flagship immunotherapy, Keytruda, accounts for roughly half of its sales, but faces a major U.S. patent cliff in 2028.
Today we announced detailed positive results from the Phase 3 INTerpath-001 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab), @Merck's anti-PD-1 therapy, in… pic.twitter.com/gZjS6m7Vpk
To cushion that impending drop, researchers are already testing the personalized vaccine platform across other difficult tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma.
excellent news on skin cancer, and perhaps for cancer in general.mRNA vaccines are turning out to be some of the best things humans have invented; crazy how politics led many people to freak out about them.https://t.co/1TJXGUCr6v
I can dream of creating a log cabin, but we got some wood chops, and we’ve just knocked down one tree. Knocking one tree does not give you a cabin or a village.
Li, via CNBC